Počet záznamů: 1
ANALYSIS OF HEMATOLOGICAL PARAMETERS IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING BIOLOGICAL THERAPY: CONTRIBUTION TO PREVENTION OF AVOIDABLE HEMATOLOGICAL COMPLICATIONS
- 1.
SYSNO ASEP 0556113 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název ANALYSIS OF HEMATOLOGICAL PARAMETERS IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING BIOLOGICAL THERAPY: CONTRIBUTION TO PREVENTION OF AVOIDABLE HEMATOLOGICAL COMPLICATIONS Tvůrce(i) Perečková, Jana (BFU-R) ORCID
Martiniakova, S. (SK)
Payer, J. (SK)
Falk, Martin (BFU-R) RID, ORCID
Killinger, Z. (SK)
Perečko, Tomáš (BFU-R) RID, ORCIDCelkový počet autorů 6 Zdroj.dok. EXCLI Journal - ISSN 1611-2156
Roč. 21, č. 2022 (2022), s. 580-594Poč.str. 15 s. Forma vydání Tištěná - P Jazyk dok. eng - angličtina Země vyd. DE - Německo Klíč. slova tumor-necrosis-factor ; factor inhibitors ; disease-activity ; tnf-alpha ; tocilizumab ; neutrophil Vědní obor RIV FA - Kardiovaskulární nemoci vč. kardiochirurgie Obor OECD Cardiac and Cardiovascular systems CEP GJ17-08066Y GA ČR - Grantová agentura ČR LTAUSA17160 GA MŠMT - Ministerstvo školství, mládeže a tělovýchovy Způsob publikování Omezený přístup Institucionální podpora BFU-R - RVO:68081707 UT WOS 000766922900001 EID SCOPUS 85126804245 DOI 10.17179/excli2022-4702 Anotace Administration of biological therapy (BT) in rheumatoid arthritis (RA) patients is often associated with hemato-logical complications, which result in switching among therapies. Thus, there is an instant need for suitable screening parameters that will help to individualize the therapy and minimize the onset of adverse effects. We analyzed the hematological profile of 99 RA patients receiving TNF-alpha (Adalimumab ADA, Golimumab GOL, Etanercept ETA) or IL-6 receptor (Tocilizumab TCZ) inhibitors in order to find possible indicators to improve personalization of RA therapy. BTs significantly affect the levels of observed hematological parameters. In contrast to TNF-alpha inhibitors, TCZ normalized almost all monitored hematological parameters to values of healthy donors. Only GOL from the TNF-alpha inhibitors studied, was able to normalize neutrophil counts, as well as platelet indicators. Importantly, effects on the blood parameters (e.g. lymphocytes or platelet count) differ even within the same therapeutic group (anti-TNF alpha). Variable effects of individual biological agents in RA treatment point to importance to evaluate the patient's hematological profile to improve the selection of suitable BT. It will help to personalize the administration of BT and prevent unnecessary switching from an effective therapy just because of provocation of avoidable hematological complications. Pracoviště Biofyzikální ústav Kontakt Jana Poláková, polakova@ibp.cz, Tel.: 541 517 244 Rok sběru 2023 Elektronická adresa https://www.excli.de/index.php/excli/article/view/4702
Počet záznamů: 1